Startseite Kongressberichte 2021 EHA2021 Virtual Congress Immunology Fungal, bacterial and viral infections in hematology

Fungal, bacterial and viral infections in hematology

Overview of Presentations with access to videos on demand (EHA subscription needed) 


Presentation ID p436-1

The study authors conclude that the BNT162b2 mRNA vaccine is exceedingly effective in producing high anti-SARS-CoV-2 antibody (NAbs and anti-spike RBD IgGs) titers in healthy donors. Given however that this readout is seemingly (up to the delivery of the second dose of the vaccine) age-dependent, the authors suggest that the second timely vaccination is needed, especially in the elderly population.


Presentation ID p436-2


Presenter: Jannik Stemler, Köln, Germany

The study authors conclude that this guideline document to help supporting the decision if to use antifungal prophylaxis in AML patients under treatment with novel agents will soon become available. It is the first one assessing this specific setting and will complement existing guidelines for antifungal prophylaxis.


The study authors conclude that in this phase II trial, a similar proportion of patients allocated to Ig and to prophylactic oral antibiotics remained alive and on their assigned treatment arm at 12 months. There was no significant difference in time to first major infection between the two treatment arms. The authors support the feasibility of proceeding with a phase III trial to compare efficacy, safety, and cost-effectiveness of Ig replacement to prophylactic oral antibiotics in patients with acquired hypogammaglobulinemia.


The study authors conclude that previous invasive fungal lung disease (IFD) history, EORTC changes & multiple non-EORTC changes at baseline CT and abnormal TLCO pre-HSCT influenced IFD related outcomes with a significant reduction survival post-IFD event. The authors suggest early respiratory optimization including focussed diagnostics in patients with abnormal pre-HSCT chest imaging, to reduce the risk of IFD-related mortality. 


The study authors conclude that infections were common in the first month following CAR-T cell administration, however were not increased in elderly patients or those presenting with poorer PS. The authors recommend that patients refractory to bridging therapy and ICANS should be monitored cautiously for the occurrence of infections and CMV monitoring should also be considered.